How to Properly Document Re-Consent During Protocol Amendments

Introduction to Re-Consent

Informed consent is not a one-time event. In clinical trials, whenever a protocol amendment introduces changes that impact participant rights, safety, or understanding of trial procedures, re-consent becomes a mandatory ethical and regulatory requirement. Re-consent ensures participants remain fully informed and that their agreement to continue participation reflects the most current trial information.

Examples of protocol amendments requiring re-consent include:

• ➤ Change in dosage regimen or study duration
• ➤ New safety findings or risks identified
• ➤ Alterations in eligibility criteria
• ➤ Modifications in study endpoints or procedures
• ➤ Updates in compensation policies

Regulatory Expectations for Re-Consent

ICH-GCP, FDA, and EMA clearly state that participants must be re-consented whenever a protocol change impacts their decision-making. IRBs and Ethics Committees review revised consent forms before implementation. Sponsors are responsible for providing clear guidance and documentation tools to ensure compliance.

Key regulatory requirements:

• FDA 21 CFR 50.25 mandates updated consent documents for new information on risks/benefits.
• EMA and EU CTR require version-controlled re-consent forms submitted to ethics committees.
• ICH-GCP 4.8.2 states informed consent should be revised whenever new information becomes available.

Step-by-Step Process for Documenting Re-Consent

A systematic approach ensures compliance and minimizes delays:

1. ➤ Draft an amended consent form in clear, layperson language.
2. ➤ Submit revised documents to the IRB/IEC for approval.
3. ➤ Train site staff on key changes before implementation.
4. ➤ Present updated consent to participants, ensuring adequate discussion.
5. ➤ Obtain signatures and date on the new version.
6. ➤ File signed forms in both participant files and the Trial Master File (TMF).

Sample Documentation Table for Re-Consent

Element	Requirement	Compliance Marker
Version Control	Unique version/date on form
Participant Signature	Updated consent signed
Investigator Signature	Verification of discussion
IRB/IEC Approval	Mandatory before implementation
Archiving	Stored in TMF and participant file

Case Study: Re-Consent in a Phase III Oncology Trial

In a Phase III oncology study, new safety data indicated higher risk of neutropenia. The sponsor amended the protocol and developed a revised consent form. After expedited IRB approval, re-consent was obtained from 95% of participants within 14 days. This transparent process prevented regulatory action and preserved participant trust. Without re-consent, the trial risked suspension and credibility damage.

Best Practices for Re-Consent

• Maintain a master log of re-consented participants with version details.
• Provide translated consent versions for non-English speakers.
• Use electronic re-consent systems with audit trails for efficiency.
• Allow sufficient time for participants to consider new information.
• Document re-consent discussions in source notes.

Conclusion

Documenting re-consent during protocol amendments is not only a regulatory requirement but also a demonstration of respect for participant autonomy. Proper documentation ensures transparency, protects participants, and maintains trial integrity. Sponsors and sites that adopt robust re-consent SOPs reduce compliance risks and strengthen relationships with regulatory authorities and participants alike.

Managing Re-Consent in Long-Term Extension Clinical Trials

As clinical research progresses beyond the primary endpoint, many trials transition into long-term extension (LTE) phases. These studies allow continued access to investigational therapies and further evaluation of long-term safety and efficacy. However, transitioning participants into LTE studies requires fresh ethical oversight — specifically, a formal re-consent process. This tutorial outlines best practices for obtaining re-consent in LTE trials, aligning with GCP, GMP documentation, and regulatory expectations.

What Are Long-Term Extension Studies?

LTE studies are follow-up clinical trials offered to participants who completed a parent study. Objectives may include:

• Monitoring long-term safety and adverse events
• Evaluating durability of efficacy
• Allowing continued therapeutic benefit post primary trial

Why Re-Consent Is Required for LTE Studies:

• The LTE phase often involves new endpoints, risks, or procedures
• Regulatory bodies such as USFDA and EMA mandate a separate informed consent for LTE participation
• Participant autonomy must be preserved; continued participation cannot be assumed
• Study protocol and Investigational Product (IP) characteristics may have evolved

Timing and Process of Re-Consent in LTE Trials:

Step 1: Draft a New Informed Consent Form (ICF)

• Clearly distinguish LTE objectives from the main study
• Include risks associated with prolonged drug exposure
• Mention new procedures or assessments, if any
• Describe duration and participant responsibilities

Step 2: Obtain Ethics Committee/IRB Approval

• Submit LTE protocol and new ICF for ethical review
• Include any updates to the Investigator’s Brochure
• Provide justifications for participant eligibility in LTE

Step 3: Train Investigators and Site Personnel

Staff must be trained on the differences between the main and extension studies. Use SOPs available at Pharma SOP templates to ensure consistency.

Step 4: Conduct Participant Re-Consent

• Offer re-consent before the first LTE visit
• Explain new objectives, risks, and timelines
• Allow time for questions and voluntary decision-making
• Document signed ICF and discussion in source notes

Elements to Include in the LTE Informed Consent Form:

• Statement clarifying LTE as a new study phase
• New data handling and reporting obligations
• Modified withdrawal criteria or safety monitoring plans
• Contact details for queries or complaints
• Updated compensation clauses (if applicable)

Participant Communication Strategies:

• Use layperson language to explain LTE differences
• Highlight changes in benefit-risk ratio
• Assure participants that refusal to participate will not impact routine care
• Use visuals and infographics for better understanding

Documentation and Record Keeping:

• File the signed LTE ICF in participant records
• Log consent in the site’s informed consent tracker
• Retain old ICFs for audit trail and regulatory inspection
• Ensure version control and track updates systematically

Audit and Regulatory Expectations:

Best Practices for Re-Consent in LTE Trials:

1. Start early — initiate LTE discussion during final visits of the main study
2. Prepare a participant handout outlining LTE rationale
3. Ensure ICF readability and comprehension assessments
4. Use AV recording for re-consent in countries like India, as per CDSCO
5. Engage LARs or caregivers when applicable

Challenges and Mitigation:

• Challenge: Participant fatigue or reluctance
• Mitigation: Emphasize continued health monitoring and access to investigational treatment
• Challenge: Delayed EC/IRB approvals
• Mitigation: Submit LTE protocols in parallel with main study closure reports
• Challenge: Multiple ICF versions
• Mitigation: Use version-controlled trackers and standardized forms

Real-World Example:

In a Phase III rheumatoid arthritis study, participants completing 48 weeks of the core study were offered entry into a 2-year LTE trial. New consent forms highlighted prolonged exposure risks, liver enzyme monitoring, and withdrawal flexibility. The IRB mandated re-consent using a clearly marked LTE ICF. As recommended on Stability Studies, detailed documentation was maintained, ensuring transparency and compliance.

Conclusion:

Re-consent in long-term extension studies is not merely an administrative requirement—it is a reaffirmation of the participant’s autonomy and the trial’s commitment to ethical conduct. A clear, timely, and well-documented re-consent process safeguards both participant rights and the integrity of clinical research. By integrating SOPs, staff training, and participant-centered communication, sponsors and sites can manage LTE transitions effectively and compliantly.